Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Total Non-current Assets
All assets not expected to be converted to cash within one year.
Tyra Biosciences, Inc.NASDAQ: TYRA
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 7.8% from a year ago
Total non-current assets stood at $17.43M at the end of Q1 FY2026, down 7.8% from a year earlier and up 1.6% from the prior quarter. Over 3 fiscal years it compounded at +24.5% a year.
Context
- Total non-current assets amounted to 4.2% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -7.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 17.16M USD
- Year-over-year change
- +6.6%
- 4-year CAGR
- +59.6%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.16M | +6.6% |
| FY2024 | 2024-12-31 | 16.1M | +13.5% |
| FY2023 | 2023-12-31 | 14.19M | +59.5% |
| FY2022 | 2022-12-31 | 8.89M | +236.3% |
| FY2021 | 2021-12-31 | 2.64M | — |
Total Non-current Assets vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's Mar 2026 total non-current assets of $17.43M is the 9th highest of the 11 companies compared; the peer median is $27.47M.
- Its year-over-year change of -7.8% is the 7th highest of 11, against a peer median of -1.0%.
- Total non-current assets amounts to 4.2% of total assets for TYRA, versus a peer median of 7.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $146.53M | +366.3% | +45.4% | 33.5% | |
| Mar 2026 | $41.58M | -84.1% | -10.7% | 10.3% | |
| Mar 2026 | $35.35M | -16.8% | -18.2% | 16.2% | |
| Mar 2026 | $34.1M | +2.5% | -13.3% | 15.4% | |
| Mar 2026 | $28.77M | +47.0% | +44.3% | 4.4% | |
| Mar 2026 | $26.18M | -4.6% | +0.1% | 2.5% | |
| Mar 2026 | $24.9M | +255.8% | +119.4% | 10.9% | |
| Jun 2026 | $18.07M | -24.8% | +69.1% | 2.4% | |
| Mar 2026 | $17.43M | -7.8% | +24.5% | 4.2% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $8.68M | +18.6% | +73.3% | 1.6% |
| Mar 2026 | $595K | -98.0% | +8.8% | 0.2% | |
| Peer median (excluding TYRA) | $27.47M | -1.0% | +26.6% | 7.4% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 302.18M | 251.21M | 58.01M | 91.97M | 77.39M |
| Short-term Investments | 0 | 0 | 145.46M | 249.48M | 178.62M |
| Net Receivables | 0 | 0 | 0 | 2M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 6.08M | 8.2M | 4.02M | 9.45M |
| Total Current Assets | 304.06M | 257.29M | 211.67M | 347.46M | 265.45M |
| Property, Plant & Equipment (Net) | 2.09M | 3.54M | 8.15M | 7.72M | 6.89M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 555K | 5.35M | 6.03M | 8.38M | 10.27M |
| Total Non-current Assets | 2.64M | 8.89M | 14.19M | 16.1M | 17.16M |
| Total Assets | 306.7M | 266.18M | 225.86M | 363.56M | 282.61M |
| Account Payables | 599K | 1.15M | 4.66M | 590K | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 412K | 472K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 5.27M | 7.14M | 10.91M |
| Total Current Liabilities | 3.62M | 5.7M | 15.33M | 14.59M | 18.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 5.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 367K | 169K | 46K | 3K | 0 |
| Total Non-current Liabilities | 1.35M | 2.65M | 6.26M | 5.81M | 5.34M |
| Total Liabilities | 4.96M | 8.35M | 21.6M | 20.41M | 23.43M |
| Common Stock | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | (40.37M) | (95.7M) | (164.83M) | (251.31M) | (371.26M) |
| Accumulated OCI | 0 | 0 | 381K | 770K | 393K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Total Debt | 1.18M | 2.62M | 6.5M | 6.22M | 5.81M |
| Net Debt | (301M) | (248.59M) | (51.51M) | (85.74M) | (71.58M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.